Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M121,566Revenue (TTM) $M37,728Net Margin (%)13.6Altman Z-Score2.1
Enterprise Value $M129,326EPS (TTM) $2.0Operating Margin %18.8Piotroski F-Score7
P/E(ttm)23.7Beneish M-Score-2.6Pre-tax Margin (%)16.4Higher ROA y-yY
Price/Book1.910-y EBITDA Growth Rate %-1.6Quick Ratio1.2Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %-4.2Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow18.3y-y EBITDA Growth Rate %-4.3ROA % (ttm)4.6Higher Current Ratio y-yY
Dividend Yield %3.5PEG--ROE % (ttm)8.3Less Shares Outstanding y-yY
Payout Ratio %86.0Shares Outstanding M2,584ROIC % (ttm)7.6Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

SNY is held by these investors:

SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-50.21view
Sanofi10% Owner 2015-01-26Buy647,448$95-50.21view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-49.23view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-29.28view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67516.69view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    Sanofi Delivers Robust Q1 2017 Financial Results Apr 28 2017 
    Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accep Apr 28 2017 
    Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (aliro Apr 25 2017 
    Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (aliro Apr 25 2017 
    Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Reject Apr 24 2017 
    Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients Apr 24 2017 
    Can Pluristem Therapeutics Corner the Acute Radiation Syndrome Market? Apr 11 2017 
    Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S. Apr 03 2017 
    Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Apr 02 2017 
    Award-Winning International Fund Manager David Herro Picks 3 Stocks Mar 03 2017 

    More From Other Websites
    Is Regeneron (Finally) Getting Back on Track? Apr 29 2017
    Regeneron (REGN) to Post Q1 Earnings: What's in the Cards? Apr 28 2017
    [$$] Sanofi 1Q Net Profit Rises on Sale of Animal-Health Unit Apr 28 2017
    ​Sarepta shares jump as CEO’s planned exit spurs takeover speculation Apr 28 2017
    Sanofi beats 1Q profit forecasts Apr 28 2017
    Yes, Sarepta Reported Earnings…But That's Not Why It's Flying Today Apr 28 2017
    Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up Apr 28 2017
    Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal Apr 28 2017
    Sanofi Delivers Robust Q1 2017 Financial Results Apr 28 2017
    Sanofi Shares Hit 18-Month High As Genzyme and Consumer Goods Deliver Strong Q1 Apr 28 2017
    Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent Apr 28 2017
    Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission... Apr 28 2017
    Amgen's Q1 Results Highlight the Need for an Acquisition Apr 27 2017
    Dupixent Expected to Be a Solid Addition to Regeneron’s Portfolio Apr 27 2017
    One in 7 people in Nevada is living with diabetes, and the state is now pushing a new approach to... Apr 26 2017
    Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Apr 26 2017
    Will Amgen's Rivals Pop On Its Cholesterol-Busting Drug? Apr 26 2017
    Why Flexion Therapeutics Inc. Stock Is Tanking Apr 26 2017
    Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product... Apr 26 2017
    K-Mart to Sell Cheaper EpiPen Alternative Apr 25 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)